Shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Get Free Report) traded down 2.4% during trading on Thursday . The stock traded as low as $1.03 and last traded at $1.04. 48,765 shares were traded during trading, a decline of 80% from the average session volume of 239,592 shares. The stock had previously closed at $1.06.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Wall Street Zen assumed coverage on shares of Can-Fite BioPharma in a research note on Thursday, April 24th. They set a “sell” rating on the stock. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, April 15th.
Check Out Our Latest Research Report on CANF
Can-Fite BioPharma Trading Down 2.4%
Hedge Funds Weigh In On Can-Fite BioPharma
An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers raised its stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 42.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,268 shares of the company’s stock after purchasing an additional 11,388 shares during the quarter. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Stories
- Five stocks we like better than Can-Fite BioPharma
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- Investing in Travel Stocks Benefits
- Is IBM’s AI Transformation Powering a Sustained Rally?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
